BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prasuhn J, Davis RL, Kumar KR. Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities. Front Cell Dev Biol 2020;8:615461. [PMID: 33469539 DOI: 10.3389/fcell.2020.615461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lang M, Grünewald A, Pramstaller PP, Hicks AA, Pichler I. A genome on shaky ground: exploring the impact of mitochondrial DNA integrity on Parkinson's disease by highlighting the use of cybrid models. Cell Mol Life Sci 2022;79:283. [PMID: 35513611 DOI: 10.1007/s00018-022-04304-3] [Reference Citation Analysis]
2 Song X, Liu P, Liu W, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima T. Protective effects of silibinin against ethanol- or acetaldehyde-caused damage in liver cell lines involve the repression of mitochondrial fission. Toxicology in Vitro 2022. [DOI: 10.1016/j.tiv.2022.105330] [Reference Citation Analysis]
3 Liu J, Jiang J, Qiu J, Wang L, Zhuo J, Wang B, Sun D, Yu S, Lou H. Urolithin A protects dopaminergic neurons in experimental models of Parkinson's disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1α signaling pathway. Food Funct 2021. [PMID: 34905594 DOI: 10.1039/d1fo02534a] [Reference Citation Analysis]
4 Litwiniuk A, Baranowska-Bik A, Domańska A, Kalisz M, Bik W. Contribution of Mitochondrial Dysfunction Combined with NLRP3 Inflammasome Activation in Selected Neurodegenerative Diseases. Pharmaceuticals (Basel) 2021;14:1221. [PMID: 34959622 DOI: 10.3390/ph14121221] [Reference Citation Analysis]
5 He L, Wang J, Yang Y, Li J, Tu H. Mitochondrial Sirtuins in Parkinson’s Disease. Neurochem Res. [DOI: 10.1007/s11064-022-03560-w] [Reference Citation Analysis]
6 Soman SK, Dagda RK. Role of Cleaved PINK1 in Neuronal Development, Synaptogenesis, and Plasticity: Implications for Parkinson's Disease. Front Neurosci 2021;15:769331. [PMID: 34795558 DOI: 10.3389/fnins.2021.769331] [Reference Citation Analysis]
7 Sá RDA, Ferreira ADS, Lemos T, de Oliveira LAS. Correlation Analysis of Lower-Limb Muscle Function With Clinical Status, Balance Tests, and Quality of Life in People With Parkinson Disease. Topics in Geriatric Rehabilitation 2022;38:56-64. [DOI: 10.1097/tgr.0000000000000343] [Reference Citation Analysis]
8 Signorile A, Ferretta A, Pacelli C, Capitanio N, Tanzarella P, Matrella ML, Valletti A, De Rasmo D, Cocco T. Resveratrol Treatment in Human Parkin-Mutant Fibroblasts Modulates cAMP and Calcium Homeostasis Regulating the Expression of Mitochondria-Associated Membranes Resident Proteins. Biomolecules 2021;11:1511. [PMID: 34680144 DOI: 10.3390/biom11101511] [Reference Citation Analysis]
9 Wang Y, Gao L, Chen J, Li Q, Huo L, Wang Y, Wang H, Du J. Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson's Disease. Front Pharmacol 2021;12:757161. [PMID: 34887759 DOI: 10.3389/fphar.2021.757161] [Reference Citation Analysis]
10 Jia F, Fellner A, Kumar KR. Monogenic Parkinson’s Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing. Genes 2022;13:471. [DOI: 10.3390/genes13030471] [Reference Citation Analysis]
11 Prasuhn J, Brüggemann N. Genotype-driven therapeutic developments in Parkinson's disease. Mol Med 2021;27:42. [PMID: 33874883 DOI: 10.1186/s10020-021-00281-8] [Reference Citation Analysis]
12 Spathopoulou A, Edenhofer F, Fellner L. Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models. Front Neurol 2022;12:786835. [DOI: 10.3389/fneur.2021.786835] [Reference Citation Analysis]
13 Kozicz T, Morava E, Yardeni T. Powering the brain in health and disease. Eur J Neurosci 2021;53:2943-5. [PMID: 33861478 DOI: 10.1111/ejn.15230] [Reference Citation Analysis]
14 Qiu J, Chen Y, Zhuo J, Zhang L, Liu J, Wang B, Sun D, Yu S, Lou H. Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson's disease model. Neuropharmacology 2022;207:108963. [PMID: 35065082 DOI: 10.1016/j.neuropharm.2022.108963] [Reference Citation Analysis]
15 Araújo de Lima L, Oliveira Cunha PL, Felicio Calou IB, Tavares Neves KR, Facundo HT, Socorro de Barros Viana G. Effects of vitamin D (VD3) supplementation on the brain mitochondrial function of male rats, in the 6-OHDA-induced model of Parkinson's disease. Neurochem Int 2022;:105280. [PMID: 35026378 DOI: 10.1016/j.neuint.2022.105280] [Reference Citation Analysis]
16 Thiankhaw K, Chattipakorn K, Chattipakorn SC, Chattipakorn N. Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognition. Biochimica et Biophysica Acta (BBA) - General Subjects 2022;1866:130097. [DOI: 10.1016/j.bbagen.2022.130097] [Reference Citation Analysis]
17 Hicke FJ, Puerta A, Dinić J, Pešić M, Padrón JM, López Ó, Fernández-Bolaños JG. Straightforward access to novel mitochondriotropics derived from 2-arylethanol as potent and selective antiproliferative agents. Eur J Med Chem 2022;228:113980. [PMID: 34847410 DOI: 10.1016/j.ejmech.2021.113980] [Reference Citation Analysis]
18 Prasuhn J, Brüggemann N. Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson's Disease. Genes (Basel) 2021;12:1840. [PMID: 34828446 DOI: 10.3390/genes12111840] [Reference Citation Analysis]